Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

USP9X decreases the amount of TP53. 2 / 2

| 2

➶

reach

"USP9X knockdown eliminated the decreased p53 expression caused by WP1130 in the presence of cisplatin."

28446729

➶

reach

"Among the compounds targeting USP9X, a non specific inhibitor of USP9X, named (EOAI3402143) G9, belonging to the USP9X-second generation inhibitors, has been shown to destabilize the pro survival protein MCL1 and increased p53 levels, promoting apoptosis in a dose dependent manner and reducing tumor growth of human myeloma xenograft [XREF_BIBR]."

32674429

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...